Maravai Lifesciences Holdings Inc (MRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Maravai Lifesciences Holdings Inc (MRVI) Earnings: Report Dates and Results
Maravai Lifesciences Holdings (MRVI) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Maravai Lifesciences Holdings reported EPS of -$0.08, below the -$0.07 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MRVI has an expected report date of Feb 23, 2027.
MRVI Earnings Call
The latest MRVI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, MRVI beat 10, missed 11 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $45.85M, up 10.1% from $41.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.08 | -$0.07 | -$0.08 - -$0.04 | -14.29% | Miss | N/A | 9 | 2 up, 4 down | Nov 4, 2026 | $45.85M |
| Jun 30, 2026 | -$0.07 | -$0.07 | N/A | 0.00% | In line | N/A | 6 | 0 up, 1 down | Aug 6, 2026 | $51.44M |
| Mar 31, 2026 | $0.01 | -$0.05 | -$0.07 - -$0.03 | +120.00% | Beat | N/A | 8 | 3 up, 2 down | May 7, 2026 | $65.84M |
| Dec 31, 2025 | -$0.04 | -$0.07 | -$0.10 - -$0.06 | +43.02% | Beat | N/A | 10 | 3 up, 3 down | Feb 25, 2026 | $49.87M |
| Sep 30, 2025 | -$0.08 | -$0.08 | -$0.12 - -$0.03 | 0.00% | In line | N/A | 11 | 4 up, 6 down | Nov 6, 2025 | $41.63M |
| Jun 30, 2025 | -$0.08 | -$0.07 | -$0.12 - -$0.03 | -14.29% | Miss | N/A | 12 | 3 up, 10 down | Aug 11, 2025 | $47.40M |
| Mar 31, 2025 | -$0.08 | -$0.07 | -$0.11 - -$0.04 | -14.29% | Miss | N/A | 14 | 0 up, 12 down | May 12, 2025 | $46.85M |
| Dec 31, 2024 | -$0.06 | -$0.04 | -$0.06 - -$0.02 | -49.63% | Miss | -700.0% | 15 | 2 up, 0 down | Mar 18, 2025 | $56.56M |
| Sep 30, 2024 | -$0.02 | -$0.01 | -$0.02 - $0.02 | -100.00% | Miss | N/A | 13 | 0 up, 0 down | Nov 7, 2024 | $69.03M |
| Jun 30, 2024 | -$0.06 | $0.00 | -$0.01 - $0.02 | N/A | N/A | N/A | 12 | 0 up, 0 down | Aug 7, 2024 | $69.42M |
| Mar 31, 2024 | -$0.02 | -$0.03 | -$0.03 - -$0.02 | +33.33% | Beat | -166.7% | 11 | 1 up, 0 down | May 8, 2024 | $64.18M |
| Dec 31, 2023 | $0.01 | -$0.01 | -$0.02 - $0.00 | +200.00% | Beat | -97.1% | 11 | 1 up, 0 down | Feb 22, 2024 | $74.14M |
| Sep 30, 2023 | -$0.01 | $0.01 | -$0.01 - $0.02 | -200.00% | Miss | -102.7% | 11 | 0 up, 0 down | Nov 7, 2023 | $66.86M |
| Jun 30, 2023 | -$0.05 | $0.01 | $0.00 - $0.04 | -600.00% | Miss | -109.3% | 12 | 0 up, 0 down | Aug 7, 2023 | $68.91M |
| Mar 31, 2023 | $0.03 | $0.04 | $0.02 - $0.06 | -25.00% | Miss | -94.4% | 12 | 0 up, 0 down | May 8, 2023 | $79.03M |
| Dec 31, 2022 | $0.35 | $0.34 | $0.32 - $0.38 | +2.94% | Beat | -22.2% | 12 | 1 up, 0 down | Feb 22, 2023 | $204.71M |
| Sep 30, 2022 | $0.37 | $0.33 | $0.29 - $0.38 | +12.12% | Beat | +311.1% | 10 | 0 up, 0 down | Nov 2, 2022 | $191.26M |
| Jun 30, 2022 | $0.54 | $0.45 | $0.39 - $0.48 | +20.00% | Beat | +22.7% | 9 | 1 up, 1 down | Aug 4, 2022 | $242.73M |
| Mar 31, 2022 | $0.54 | $0.44 | $0.41 - $0.46 | +22.73% | Beat | +2600.0% | 9 | 1 up, 0 down | May 5, 2022 | $244.29M |
| Dec 31, 2021 | $0.45 | $0.38 | $0.35 - $0.43 | +18.42% | Beat | +246.2% | 9 | 0 up, 0 down | Feb 23, 2022 | $228.44M |
| Sep 30, 2021 | $0.09 | $0.17 | N/A | -47.06% | Miss | N/A | 9 | N/A | Nov 10, 2021 | $204.81M |
| Jun 30, 2021 | $0.44 | $0.02 | N/A | N/A | N/A | N/A | 10 | N/A | Aug 10, 2021 | $217.78M |
| Mar 31, 2021 | $0.02 | $0.07 | N/A | -71.43% | Miss | N/A | 10 | N/A | May 10, 2021 | $148.21M |
| Dec 31, 2020 | $0.13 | $0.11 | $0.05 - $0.17 | +18.18% | Beat | N/A | 10 | N/A | Mar 2, 2021 | $98.35M |
| Sep 30, 2020 | -$0.02 | $0.17 | N/A | -111.76% | Miss | N/A | N/A | N/A | Nov 23, 2020 | $87.86M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.28, after -$0.16 the year before. It was $0.11 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.28 | N/A |
| Dec 31, 2024 | -$0.16 | N/A |
| Dec 31, 2023 | -$0.02 | -101.1% |
| Dec 31, 2022 | $1.80 | +80.0% |
| Dec 31, 2021 | $1.00 | +809.1% |
| Dec 31, 2020 | $0.11 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,279 | 12 | |
| 2026Q2 | Jun 30, 2026 | 5,118 | 11 | |
| 2026Q1 | Mar 31, 2026 | 4,981 | 11 | |
| 2025Q4 | Dec 31, 2025 | 6,319 | 13 | |
| 2025Q3 | Sep 30, 2025 | 5,457 | 11 | |
| 2025Q2 | Jun 30, 2025 | 8,008 | 15 | |
| 2025Q1 | Mar 31, 2025 | 8,123 | 12 | |
| 2024Q4 | Dec 31, 2024 | 8,634 | 14 |
2026Q3 Earnings Call
Opening remarks
Debra Hart Executive Good afternoon, everyone. Thanks for joining us for our third quarter 2026 earnings call. The press release and the slides that accompany today's call are available at investors.maravai.com. As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update, and our CFO, Rajesh J. Asorpota, will review our financial results. Dr. Chanfeng Zhao, our Chief Scientific Officer, and Kurt Oreshack, our executive vice president and general counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from expectations, and we undertake no obligation to update them. We refer you to Slide 3 for details on our forward-looking statements, and Slide 4 for our use of non-GAAP financial measures. The press release and the slides provide reconciliations to the directly comparable GAAP measures, and we also post reconciling schedules to our investor website. Please also refer to the risk factors in Maravai's annual report on Form 10-K for 2025, our subsequent quarterly reports on Form 10-Q, and our other SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I will turn the call over to Bernd.
Bernd Brust CEO Good afternoon, and thank you for joining us. We are pleased with our third quarter performance, which builds on the momentum we established in the first half of the year. Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy. During the quarter, we generated revenue of $45.9 million, representing 10% year-over-year growth. TriLink revenue increased 12%, led by strong demand for our mRNA products. mRNA revenue was up 28% year over year. Within mRNA, GMP consumables grew 30%, and discovery was up 27%. We had no high-volume CleanCap revenue for commercial-phase COVID vaccine programs in the quarter. CDMO revenue grew 8%, while specialty chemistry was down 4% as some large orders from Q3 of 2025 did not repeat in the quarter this year. Cygnus also delivered a solid quarter, with revenue growing 8%. This is the sixth consecutive quarter of year-over-year growth for Cygnus. From a profitability standpoint, adjusted gross margin expanded more than 1,700 basis points year over year to 57.7%, while adjusted EBITDA improved by $16.6 million to $5.8 million. These results reflect higher revenue, a favorable product mix, and the benefits of the operating model we have built over the past year. Now let's turn to Slide 7 and highlight some of the landmark clinical progress we are seeing in our largest, most strategic part of the business, the mRNA market.
Frequently Asked Questions About MRVI
When is Maravai Lifesciences Holdings's next earnings date?
Maravai Lifesciences Holdings's next earnings report is expected for Feb 23, 2027.
Did MRVI beat earnings estimates last quarter?
No. Maravai Lifesciences Holdings reported EPS of -$0.08 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 14.29%.
What EPS do analysts expect from MRVI next quarter?
The consensus EPS estimate for Maravai Lifesciences Holdings for the quarter ending Dec 31, 2026 is -$0.04 from 11 analysts, with estimates from -$0.06 to -$0.02.
How often does MRVI beat earnings estimates?
Maravai Lifesciences Holdings beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +8.82%.
MRVI pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors